The Advanced Microscopy Facility (AMF) is a matrix Cancer Center shared resource, which operates under the auspices of the Office of Research Core Administration, a department within the University of Virginia (UVA) School of Medicine (SOM). Since the first Cancer Center Support Grant to UVA in 1987, the AMF has provided Cancer Center investigators with unique access to instrumentation and services for visualization of biological processes and structures. As microscopy has become an indispensable and near universal tool for biomedical research, access to cutting edge microscopy equipment at the AMF has allowed Cancer Center members to make important discoveries regarding the cause, spread, and treatment of cancer. The AMF's primary mission is to serve the imaging needs and enable the exceptional cancer research at the University of Virginia.
The specific aims are to house and provide affordable access to state-of-the-art microscopy instrumentation and high-quality imaging services, empower Cancer Center investigators in the practice and science of imaging, and built a nexus for collaboration among the AMF users. The facility, which is both a full-service and a user-facility, has been expanded from primarily an electron microscopy center to now encompass a full range of light and electron microscopy technologies. The SOM has continued to support the AMF and since the last CCSG review and has made substantial investment (~$7 million) to establish the cryo-microscopy services. The institutional support and funds from NIH shared instrumentation grants have allowed the AMF to acquire an impressive array of state-of-the-art microscopes, including three confocal microscopes with super-resolution or two-photon imaging capabilities, and a 300 kV Titan Krios transmission electron microscope equipped with a direct electron detector, available at only a handful North American institutions. Providing Cancer Center members with access to electron cryo- microscopy services is a major advancement of the AMF's capabilities. The facility was rated ?outstanding? in the last review. The AMF staff have worked to further enhance the capabilities of the shared resource to provide exceptional services to Cancer Center researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-30
Application #
10091425
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-09-16
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
30
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications